Ionis Pharmaceuticals Inc (NASDAQ: IONS) has reported E.P.S. of $-0.66 for its fourth fiscal quarter (ending December 31) versus $-0.06 for the same period a year ago — an increase of 1000%. E.P.S. were $-3.04 for the latest four quarters through December 31 versus $-2.56 for the same period a year ago — an increase of 19%.
Recent Price Action
Ionis Pharmaceuticals Inc (NASDAQ: IONS) stock declined slightly by -0.4% on 2/19/25. The stock closed at $31.81. Moreover, exceptionally high trading volume at 206% of normal accompanied the decline. The stock has been weak relative to the market over the last nine months but has risen 1.0% during the last week.
Current PriceTarget Research Rating
Ionis Pharmaceuticals has a current Value Trend Rating of F (Lowest Rating). This rating combines consistent signals from two proprietary PTR measures of a stock’s attractiveness. Ionis Pharmaceuticals has a poor Power Rating of 21 and a very low Appreciation Score of 5, triggering the Lowest Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment